undergo Sea Changes

Scientific Advisory Board to undergo Sea Changes; Thanks to severity of Alzheimer’s Disease!

Synaptogenix, on July 26, 2022, did announce that it had made alterations to its SAB (Scientific Advisory Board) with regards to preparing for Phase 2 data, that too, from its Phase 2b clinical trial of Bryostatin-1 for those contracting moderately severe and advanced AD (Alzheimer’s Disease). SAB constitutes academic and industry leaders in drug development […]

Continue Reading